Depakote belongs to a class of medications called antiepileptic drugs (AEDs), also known as anticonvulsants. Depakote is a brand-name drug manufactured by AbbVie and approved by the U.S. Food and Drug Administration (FDA) to treat epilepsy and bipolar disorder. It is also FDA approved for the prevention of migraines. The medication is also manufactured by several other companies and sold under the generic name divalproex sodium. The chemical structure of Depakote is similar to the brand name Depakene (valproic acid). While the two have similar uses, they are not interchangeable and come in different dosage forms.
Depakote is available in three oral formulations: delayed-release tablets, extended-release tablets (Depakote ER), and delayed-release sprinkle capsules (Depakote Sprinkles). Depakote ER allows for once-daily dosing, and sprinkle capsules allow Depakote to be mixed into soft food such as applesauce, yogurt, pudding, oatmeal, or ice cream.
Delayed-release tablets: 125 mg, 250 mg, and 500 mg
Extended-release tablets: 250 mg and 500 mg
Delayed-release sprinkle capsules: 125 mg
Check our best Depakote prices
Depakote dosage chart |
|||
|---|---|---|---|
| Indication | Starting dosage | Standard dosage | Maximum dosage |
| Acute manic bipolar disorder | 250 mg 3x/day Extended-release: 25 mg/kg/day as a single dose | 500 mg 3x/day Extended-release: 2000 mg/day | 60 mg/kg daily, no single dose should exceed 250 mg |
| Complex partial seizures | 10-15 mg/kg/day, divided into 1-3 doses. Increase by 5-10 mg/kg/day every 7 days. | 30-60 mg/kg/day, divided into 2-3 doses Extended-release: 30-60 mg/kg/day as a single dose | 60 mg/kg/day, no single dose should exceed 250 mg |
| Simple and complex absence seizures | 15 mg/kg/day, divided into 1-3 doses. Increase by 5-10 mg/kg/day every 7 days. | 30-60 mg/kg/day, divided into 2-3 doses Extended-release: 30-60 mg/kg/day as a single dose | 60 mg/kg daily, no single dose should exceed 250 mg |
| Migraine prevention | 250 mg 2x/day | 500 mg 2x/day | 1500 mg/day |
Depakote is a first-line therapy for patients diagnosed with bipolar disorder. It may be used alone (monotherapy) or in combination with other medications such as aripiprazole for the treatment of acute mania. Combination therapy may be more effective and provide faster benefits when compared with monotherapy.
Starting dosage for acute manic bipolar disorder: 500–750 mg per day (or 25 mg/kg daily) and increase the dose by 30% to 50% every three days as tolerated
Standard dosage for acute manic bipolar disorder: 1,000–3,000 mg daily to maintain
Depakote blood levels between 50-125 mcg/mL
Depakote blood levels are typically monitored every one to two weeks during the first two months of therapy, then every three to six months.
Depakote may be prescribed for absence seizures (which affect both sides of the brain) or partial seizures (which affect just one area of the brain). Absence seizures involve a sudden and brief lapse of consciousness, manifested as rapid blinking or a momentary blank expression. Partial seizures may involve muscle contractions, muscle weakness, unusual heady or eye movements, abdominal pain, increased heart rate, dilated pupils, changes in vision, hallucinations, numbness, or tingling.
Partial seizures can be further categorized as simple or complex. During a simple partial seizure, the patient does not lose consciousness. During a complex partial seizure, the patient loses consciousness and does not remember what happened.
Depakote dosage for epilepsy: 10-15 mg/kg or 250-750 mg of Depakote per day. The dose is increased by 5-10 mg/kg or 250-500 mg daily each week until seizures stop
Doctors will adjust the dose to minimize adverse reactions and to maintain levels of Depakote in the blood between 50-1000 mcg/mL.
Depakote is a first-line agent for the prevention of migraines. According to an analysis of 10 different studies, 1 out of 5 patients 16 years and older experienced a 50% reduction in migraine frequency when taking Depakote. Blood levels of the Depakote do not usually need to be monitored, although they may be useful for patients on the higher end of the dosage range to reduce risks of toxic side effects.
Starting dosage migraines: 250 mg twice daily (the dose may be increased to 1500 mg daily in divided doses if needed)
Standard Depakote dosage for children ages 10 and above: 30-60 mg/kg daily, divided into two or three doses
Maximum Depakote dosage for children ages 10 and above: Total daily doses should not exceed 60 mg/kg daily. Any single dose should not exceed 250 mg
Depakote dosage for children |
|||
|---|---|---|---|
| Indication | Form | Recommended dosage | Maximum dosage |
| Complex partial seizures | Extended-release tablets | Start with 10-15 mg/kg/day divided into 1-3 doses; increase by 5-10 mg/kg/day every 7 days | Any single dose should not exceed 250 mg |
| Simple and complex absence seizures | Delayed-release sprinkle capsules | Start with 15 mg/kg/day divided into 1-3 doses; increase by 5-10 mg/kg/day every 7 days | Any single dose should not exceed 250 mg |
Depakote contraindications (should not be used) include patients with POLG-related mitochondrial disorders (e.g., Alpers Huttenlocher Syndrome) due to an increased risk of liver failure and death when taking Depakote.
Patients diagnosed with pancreatitis should discontinue Depakote and start an alternative treatment. Life-threatening pancreatitis has occurred in adults and children shortly after starting Depakote therapy or several years into therapy. Signs and symptoms of pancreatitis include abdominal pain (stomach pain that radiates to your back), nausea, vomiting, and weight loss or anorexia.
Adults and children with liver disease should avoid using Depakote if other treatment options are available. Patients younger than 2 years may experience fatal liver toxicity (hepatotoxicity) when using Depakote, especially when used with other seizure medications. If no alternative treatment options are available, use Depakote with extreme caution and as monotherapy in this age group.
Older patients are more predisposed to Depakote’s side effects such as tremors or drowsiness. Depakote should be started at a low dose in seniors compared to younger adults, and doses should be increased gradually to achieve effective treatment.
You may open the capsule and pour the medicine onto a teaspoonful of soft food (including pudding or applesauce). Stir this mixture well and swallow it without chewing.
Part of the medicine may pass into your stool after your body has absorbed the medicine. Check with your doctor right away if this happens.
This medicine should come with a medication guide. Ask your pharmacist for a copy if you do not have one.
Take your medicine as directed. Your dose may need to be changed several times to find what works best for you.
You may take this medicine with food to decrease stomach upset.
Swallow the medicine whole. Do not crush, break, or chew it.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light.
Depakote tablets reach peak levels in four hours, while the sprinkle capsules reach peak levels in three hours. Food can delay the absorption of Depakote, especially the tablets (absorption of tablets can take up to eight hours when taken with food). The time to absorption may differ depending on the administration method, for example, whether the contents of the capsule are sprinkled on food, or the capsule is swallowed whole. However, the administration method will not impact the effectiveness of Depakote.
The effects of Depakote are experienced after a period of regular use. For Depakote to have its effects, it must reach a stable concentration, called “steady state.” This condition is usually achieved in two to five days, depending on the patient’s age and weight. Once a steady-state is achieved, doctors can begin to assess how well Depakote is working and decide if a dose adjustment is needed. When starting Depakote, multiple dosage adjustments over a few weeks may be necessary before a patient notices an improvement in symptoms.
Healthcare professionals measure the time it takes to eliminate a drug from the body using a metric called a half-life; this is the time it takes the body to get rid of half the amount of drug currently in your system.
The half-life of Depakote depends on several factors such as a patient’s age, kidney, and liver function, how often Depakote is taken, and other medications that may interact with Depakote. When taken by itself, the half-life of Depakote is roughly 14 hours, and it takes five half-lives to eliminate most drugs. So, while the levels of Depakote may not be high enough to have clinical effects, Depakote can remain in your system for about three days following a single dose.
Certain medications decrease the time it takes to clear Depakote from the body. For example, other seizure medications like carbamazepine, phenytoin, and phenobarbital can double the rate that Depakote is cleared. One study determined that taking 600 mg of rifampin daily increased the clearance rate of Depakote by 40%.
If you miss a dose of Depakote, take the missed dose as soon as you can. However, you should skip the missed dose if it is almost time for your next dose.
If you take Depakote once daily, and it is less than 12 hours until your next dose, skip the missed dose and take the next dose at the usual time.
If you take Depakote two or three times daily, and it is less than two hours before the next dose is due, skip the missed dose and take your next dose at the usual time.
Do not take two doses at one time.
Missing doses of Depakote can increase your risk for recurrence of seizures or manic episodes, and the risk increases with each consecutive missed dose. It is best to take Depakote at the same time each day to help you remember each dose. Always remember to get your prescription refilled before you run out of medicine completely.
Depakote is intended for long-term use. Long-term Depakote treatment increases the risk for osteoporosis, blood clots, and liver damage. However, for many patients, the benefits of Depakote greatly outweigh these risks. Patients with epilepsy or bipolar disorder typically require lifelong treatment and they should not stop taking Depakote without talking to a doctor.
Do not stop taking Depakote without asking your doctor. Abruptly stopping Depakote can result in withdrawal seizures and relapses in mood disorder symptoms. If a doctor decides to discontinue Depakote, the dose must be gradually decreased (tapered) before it is stopped completely. The length of the tapering period depends on the medical condition being treated, the use of monotherapy vs. multiple medications to manage the condition, and patient-specific risk factors for relapse. In adults, Depakote is often decreased over six months, and in children between six weeks and nine months.
Taking too much Depakote can result in central nervous system dysfunction, liver toxicity, and pancreatitis. Symptoms can include vomiting, diarrhea, tremors, agitation, confusion, altered mental status, and seizures. Liver problems may not be evident upon examination but will manifest as elevated liver enzymes on a blood test. Acute overdoses can cause a brain condition called encephalopathy which may result in coma and death. Call poison control at 1 (800) 222-1222 if you suspect a Depakote overdose.
Other antiepileptic drugs such as carbamazepine, phenytoin, and phenobarbital can lower the levels of Depakote, and may require increased doses of Depakote to avoid relapses in mood symptoms or seizures.
Other interactions include:
Salicylates (aspirin, magnesium salicylate, etc.)
Certain medications such as estrogen-containing birth control and a class of antibiotics called carbapenems (imipenem, meropenem, etc.)
Extra caution must be exercised when combining Depakote with lamotrigine due to the increased risk of a serious rash called Stevens-Johnsons Syndrome (SJS).
This is not an exhaustive list of all Depakote drug interactions. It is best to consult with a healthcare provider about potential interactions with other medications you are taking.
Taking Depakote for epilepsy or bipolar disorder does not necessarily mean you can’t take alcohol. Alcohol can worsen some adverse effects of Depakote, including dizziness, drowsiness, and lowered concentration. It can also increase the chances of having a seizure, even in patients without epilepsy. Combining alcohol and Depakote can also increase impulsive behavior, suicidal thoughts, injury, and hospitalization in patients with bipolar disorder. In general, it is best to limit or avoid alcohol while taking Depakote.
Taking Depakote during pregnancy increases the risk for birth defects such as congenital neural tube defects (spina bifida), and congenital malformations of the heart, limbs, and genitals. It may also result in decreased IQ scores and neurodevelopmental disorders such as autism in the child. Pregnant women should only use Depakote for epilepsy or bipolar disorder if alternative treatment options are not feasible. Depakote should not be used for migraine prevention in women who are pregnant or women of childbearing potential without effective contraception.
Depakote is transferred to the infant in limited amounts while breastfeeding. Possible risks include liver damage in the infant. For this reason, some doctors recommend against using Depakote for conditions other than epilepsy while breastfeeding. If a patient is taking Depakote for a seizure disorder while breastfeeding, the benefits of Depakote are greater than any potential risks to the infant.
Daniel Cardin, Pharm.D., graduated from the University of North Carolina School of Pharmacy. He is a Connecticut-based pharmacist and freelance writer focused on drug information and healthcare topics. He has worked in hospital and community pharmacies in various roles, including research, clinical pharmacy, and pharmacy management.
...Health education, drug info, wellness & more
Prescription savings vary by prescription and by pharmacy, and may reach up to 80% off cash price. This is a medical discount plan. This is NOT insurance. This program offers you the opportunity to locate providers of various types of medical services who will offer their services to you at discounted rates. The range of discounts for medical or ancillary services provided under the plan will vary depending on the type of provider and service received. You are fully responsible for paying for all health care services but will be entitled to receive a discount from those health care providers in accordance with the specific pre-negotiated discounted fee schedule. This program does not guarantee the quality of the services or procedures offered by the providers. Except for prescription drugs which you will pay directly to the pharmacy at the time of purchase, all other services received through a program provider will be charged to the credit card on file in your member account. The charge will include an administrative fee for use of the program. Towers Administrators LLC is the licensed discount medical plan organization with its administrative office located at 4510 Cox Road, Suite 111, Glen Allen, VA 23060. SingleCare Services, LLC is the marketer of the discount medical plan organization including its website, singlecare.com, with its corporate office located at 99 High Street, Suite 2800, Boston, MA 02110. For additional information, including an up-to-date list of providers, or assistance with any issue related to program membership, please contact member support any time at www.singlecare.com, or by calling toll-free 844-234-3057, 24 hours, 7 days a week (except major holidays). Pharmacy names, logos, brands, and other trademarks are the property of their respective owners.
Blog articles are not medical advice. They are intended for general informational purposes and are not meant to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. If you think you may have a medical emergency, immediately call your physician or dial 911.
© 2025 SingleCare Administrators. All rights reserved
© 2025 SingleCare Administrators. All rights reserved